|
|
 |
|
Viewing report
|
|
|
|
Top 20 Therapy Cancer Brands - Key Brands Set to Consolidate Advantage as Competition Intensifies
Datamonitor, Aug 2008, Pages: 401
Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.
Scope
- Current and future overview of the cancer therapy brands market in 2007 and 2017
- Individual country forecasts for the Top 20 cancer therapy brands in each of the seven major markets
- Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events
- Detailed product profiles and discussion of assumptions and events used in forecast analysis
Highlights
The Top 20 cancer therapy brands in the seven major markets contributed the majority ($26.1 billion, 85%) of cancer therapy brand sales in 2007. Datamonitor forecasts the total market to grow to $62.4 billion by 2017 at a CAGR of 7%. The Top 20 brands in 2017 will still contribute a high proportion of this (80%) with sales reaching $50.2 billion.
Targeted therapies will increasingly dominate the Top 20 cancer brands leaderboard, accounting for 12 of the Top 20 brands in the seven major markets in 2017. Datamonitor forecasts Avastin to become the leading cancer therapy brand, facilitated by further indication expansion and high physician familiarity.
Genentech/Roche are the dominant force in the market with an oncology portfolio including the three leading cancer therapy brands (Rituxan, Avastin and Herceptin). The companies are set to continue this dominance, with Rituxan, Avastin and Herceptin forecast to remain the top three brands in 2017, achieving aggregate 7MM sales of over $23 billion.
Reasons to Purchase
- Understand market specific drivers and predict the future potential of key cancer therapy brands
- Quantify the impact of key patent expiries and product launches and gain a valuable insight into the market dynamics
- Consider, assess and react to opportunities and risks influencing the leading cancer therapy brands
Customers who bought this item also bought
Commercial Insight: Targeted Therapy Cancer Brands - High Growth Market will see Eight New Blockbusters by 2017
Forecast Insight: Top 20 Cancer Therapy Brands
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
Antihormonal Therapy Cancer Brands - Careful Lifecycle Management Needed to Preserve Brand Dominance
Top 20 Cancer Therapy Brands Forecast
Commercial Insight: Antihormonal Cancer Therapies
Cancer Therapeutics Markets
Cancer Therapies - Global Strategic Business Report
The Cancer Market Outlook to 2012
Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
Commercial Insight Top 20 Cancer Therapeutics
|
|
|
|
